Review summarizes FTO's oncogenic and tumor-suppressive roles in cancer, indicating therapeutic implications.
N6-methyladenosine (m 6 A), the most abundant mRNA modification, is dynamically regulated by the "writer–eraser–reader" system. Within this system, FTO constitutes a core component of the m 6 A demethylase enzymes. Accumulating evidence demonstrates that FTO plays pivotal roles in various cancer types through its m 6 A demethylase activity. While the implications of m 6 A modifications in cancer pathogenesis have been extensively reviewed, the critical functions of FTO across diverse malignancies and its potential as a therapeutic target remain less explored. This review summarizes current evidence on the oncogenic and tumor-suppressive roles of FTO in different cancers, elucidates the underlying molecular mechanisms, and discusses the potential for targeting FTO therapeutically.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: